Jacobs Levy Equity Management’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Jacobs Levy Equity Management’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-20,166	Closed	-$223K	–	1123
2020 Q3	$223K	Sell	20,166 -1,810	-8%	-$12.5K	﹤0.01%	945
2020 Q2	$163K	Buy	+21,976	New	+$147K	﹤0.01%	978
2020 Q1	–	Sell	-57,969	Closed	-$291K	–	1130
2019 Q4	$291K	Buy	+57,969	New	+$368K	﹤0.01%	860

Other funds holding KLDO

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's KLDO Position: Q4 2020 in Review

Jacobs Levy Equity Management sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q4 2020, closing a stake of 20,166 shares — an estimated $223K sold.

Jacobs Levy Equity Management first reported a position in KLDO in Q4 2019 and held it in 3 quarters. The position peaked at $291K in Q4 2019. 61 funds tracked by Wall St. Rank hold KLDO as of Q4 2020.

Jacobs Levy Equity Management reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Jacobs Levy Equity Management sold 20,166 Kaleido Biosciences, Inc. Common Stock shares in Q4 2020, an estimated $223K.
Jacobs Levy Equity Management first reported a position in Kaleido Biosciences, Inc. Common Stock in Q4 2019 and held it in 3 quarters.
Jacobs Levy Equity Management's Kaleido Biosciences, Inc. Common Stock position peaked at $291K in Q4 2019.
61 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q4 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2020, filed 16 Feb 2021.